Treatment with anti-sclerostin antibody does not have an impact on tumor burden. (A) Representative flow cytometry plots of 5TGM1-eGFP control-treated bone marrow and 5TGM1-eGFP anti-sclerostin antibody–treated bone marrow showing the percentage of 5TGM1-eGFP⁺ cells in the sample (black box). (B) Dot plots of bone marrow tumor burden as a percent of total bone marrow cells (% GFP⁺) in experiments 1 and 2 of the 5TGM1 study (n = 6 [experiment 1]; n = 8 [experiment 2]). Data are mean ± 1 SEM. (C) Dot plots of spleen tumor burden as a percent of total cells (% GFP⁺) in experiments 1 and 2 of the 5TGM1 study (n = 6 [experiment 1]; n = 8 [experiment 2]). Data are mean ± 1 SEM. (D) Dot plots of bone marrow and spleen tumor burden (% idiotype⁺) in the 5T2MM study (n = 6-7). Data are mean ± 1 SEM. (E) Dot plots of whole body tumor burden (total flux p/s) and bone marrow percent GFP⁺ cells in MM1.S experiment 1 (n = 9 per group). Data are mean ± 1 SEM; *P < .05. (F) Dot plots of whole body tumor burden (total flux p/s) at 3 weeks and bone marrow percent GFP⁺ cells in MM1.S experiment 2 (n = 8-9 for whole body tumor; n = 5-9 for bone marrow tumor). Data are mean ± 1 SEM.